Parties to implement a pilot program of the
Veris Cancer Care Platform
NEW YORK,
April 30,
2024 /PRNewswire/ -- PAVmed Inc. (Nasdaq:
PAVM) ("PAVmed" or the "Company") a diversified commercial-stage
medical technology company, operating in the medical device,
diagnostics, and digital health sectors, and its majority-owned
digital health subsidiary Veris Health Inc. ("Veris"), today
announced that Veris and The Ohio State
University Comprehensive Cancer Center – Arthur G. James
Cancer Hospital and Richard J. Solove Research Institute (the
"OSUCCC – James"), a National Cancer Institute-Designated
Comprehensive Cancer Center, have executed a memorandum of
understanding to implement a pilot program where cancer patients
would be enrolled on the Veris Cancer Care Platform™.
"The OSUCCC – James is one of the largest and
most prestigious academic cancer centers in the nation and we
couldn't be more excited to work with such a renowned institution
at the forefront of cancer care during the pilot program," said
Lishan Aklog, M.D., PAVmed's
Chairman and Chief Executive Officer and Veris' Executive
Chairman.
"Our vision is to enhance personalized cancer
care through the use of cutting-edge digital health tools," said
Gary K. Manning, Veris' President.
"We look forward to completing a successful pilot program and to
offering enhanced personalized cancer care to the thousands of
patients who receive systemic cancer therapy there every year."
"At the OSUCCC – James, personalized,
compassionate cancer care is at the core of what we do. Remote
monitoring allows for the integration of expert, sub-specialized
oncology care in a patient's own home, surrounded by their support
system. This component of the cancer care continuum is yet another
way we are engaging in the future of cancer care and is in line
with our pursuit of a cancer-free world," said David Cohn, M.D., M.B.A., interim chief
executive officer and chief medical officer at The James Cancer
Hospital and Solove Research Institute.
The Veris Cancer Care Platform is a comprehensive
digital cancer care platform with remote physiological data
collection, symptom reporting, telehealth capability, and
electronic health record integration. The platform offers enhanced
personalized cancer care through the early detection of
complications, reduced unplanned hospitalizations, the provision of
longitudinal trends of physiological and clinical data, data-driven
risk management tools, and increased patient and provider
satisfaction.
Cancer patients enrolled on the platform receive
a VerisBox™ of Veris-branded connected health care devices which
transmit physiologic data to the cloud-based clinician portal via
embedded cellular connections. A complementary patient portal
enables patients to report symptoms, as well as general health and
quality of life parameters, to their cancer care team through the
Veris patient smartphone app. The app also allows caretakers and
family members to follow along on the patient's cancer care
journey. Veris is also developing an implantable physiological
monitor, designed to be implanted alongside a vascular access port,
which will interface with the Veris Cancer Care Platform. The
implantable monitor will further enhance the clinical and
commercial value of the platform by providing remote physiologic
data independent of patient compliance.
Cancer centers and oncology practices interested
in learning more about Veris and the Veris Platform, please visit
www.verishealth.com to contact a company representative.
About PAVmed and Veris
PAVmed Inc. is a diversified commercial-stage
medical technology company operating in the medical device,
diagnostics, and digital health sectors. Its majority-owned
subsidiary, Veris Health Inc., is a digital health company whose
lead product is a digital cancer care platform with physiologic
data collection, symptom reporting and telehealth functions,
designed to improve personalized cancer care through remote patient
monitoring. Veris has also been developing an implantable
physiological monitor, designed to be implanted alongside a
chemotherapy port, which will interface with the Veris cancer care
platform. Its other majority-owned subsidiary, Lucid Diagnostics,
is a commercial-stage cancer prevention medical diagnostics company
that markets the EsoGuard® Esophageal DNA Test and
EsoCheck® Esophageal Cell Collection Device—the first
and only commercial tools for widespread early detection of
esophageal precancer to mitigate the risks of esophageal cancer
deaths.
For more and for more information about PAVmed,
please visit pavmed.com.
For more information about Veris Health, please
visit verishealth.com.
For more information about Lucid Diagnostics,
please visit luciddx.com.
About The Ohio State
University Comprehensive Cancer Center – Arthur G. James
Cancer Hospital and Richard J. Solove Research Institute
The Ohio State
University Comprehensive Cancer Center – Arthur G. James
Cancer Hospital and Richard J. Solove Research Institute (the
"OSUCCC – James"), is the only cancer program in the United States that features a National
Cancer Institute (NCI)-designated comprehensive cancer center
aligned with a nationally ranked academic health center and a
freestanding cancer hospital on the campus of one of the nation's
largest public universities.
The OSUCCC – James has been designated as an NCI
Comprehensive Cancer Center since 1976. Also, it is one of only a
few centers funded by the NCI to conduct both phase I and phase II
clinical trials on novel anticancer agents provided by the NCI.
As the cancer program's adult patient-care
component, The James is one of the top cancer hospitals in the
nation as ranked by U.S. News & World Report for 25
years and has achieved Magnet® recognition, the highest honor an
organization can receive for quality patient care and professional
nursing practice. With 21 floors, more than 1.1 million square feet
and 356 inpatient beds, The James is the third-largest cancer
hospital in the nation.
The OSUCCC – James is a global leader in such
emerging disciplines as cellular therapy and immuno-oncology. In
2017, the OSUCCC – James was among the first hospitals in
the United States to offer the
first cellular therapy for blood cancers, known as CAR T-cell
therapy, and is playing a major role in the continuing development
of this and other cellular therapies.
To learn more about cancer treatment and clinical
trials at the OSUCCC – James, visit cancer.osu.edu.
Forward-Looking Statements
This press release includes forward-looking
statements that involve risk and uncertainties. Forward-looking
statements are any statements that are not historical facts. Such
forward-looking statements, which are based upon the current
beliefs and expectations of PAVmed's management, are subject to
risks and uncertainties, which could cause actual results to differ
from the forward-looking statements. Risks and uncertainties that
may cause such differences include, among other things, volatility
in the price of PAVmed's common stock; general economic and market
conditions; the uncertainties inherent in research and development,
including the cost and time required to advance PAVmed's products
to regulatory submission; whether regulatory authorities will be
satisfied with the design of and results from PAVmed's clinical and
preclinical studies; whether and when PAVmed's products are cleared
by regulatory authorities; market acceptance of PAVmed's products
once cleared and commercialized; PAVmed's ability to raise
additional funding as needed; and other competitive developments.
These factors are difficult or impossible to predict accurately and
many of them are beyond PAVmed's control. In addition, new risks
and uncertainties may arise from time to time and are difficult to
predict. For a further list and description of these and other
important risks and uncertainties that may affect PAVmed's future
operations, see Part I, Item 1A, "Risk Factors," in PAVmed's most
recent Annual Report on Form 10-K filed with the Securities and
Exchange Commission, as the same may be updated in Part II, Item
1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by
PAVmed after its most recent Annual Report. PAVmed disclaims any
intention or obligation to publicly update or revise any
forward-looking statement to reflect any change in its expectations
or in events, conditions, or circumstances on which those
expectations may be based, or that may affect the likelihood that
actual results will differ from those contained in the
forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/pavmed-subsidiary-veris-health-signs-memorandum-of-understanding-with-the-ohio-state-university-comprehensive-cancer-center--james-cancer-hospital-and-solove-research-institute-302130843.html
SOURCE PAVmed Inc.